Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21.

2.

Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.

Mueller MS, Shakeri-Nejad K, Gutierrez MM, Krause A, Täubel J, Sanderson B, Dingemanse J.

J Cardiovasc Pharmacol. 2014 Feb;63(2):120-31. doi: 10.1097/FJC.0000000000000030.

PMID:
24126567
3.

Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Tamborrini M, Mueller MS, Stoffel SA, Westerfeld N, Vogel D, Boato F, Zurbriggen R, Robinson JA, Pluschke G.

Malar J. 2009 Dec 30;8:314. doi: 10.1186/1475-2875-8-314.

4.

MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses.

Beck IM, Rückert R, Brandt K, Mueller MS, Sadowski T, Brauer R, Schirmacher P, Mentlein R, Sedlacek R.

PLoS One. 2008 Jun 4;3(6):e2343. doi: 10.1371/journal.pone.0002343.

5.

Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.

Okitsu SL, Mueller MS, Amacker M, Vogel D, Westerfeld N, Robinson JA, Zurbriggen R, Pluschke G.

Hum Vaccin. 2008 Mar-Apr;4(2):106-14. Epub 2007 Oct 18.

PMID:
18382133
6.

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, Zurbriggen R, Pluschke G.

PLoS One. 2007 Dec 5;2(12):e1278.

7.

Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites.

Okitsu SL, Boato F, Mueller MS, Li DB, Vogel D, Westerfeld N, Zurbriggen R, Robinson JA, Pluschke G.

Peptides. 2007 Oct;28(10):2051-60. Epub 2007 Aug 17.

PMID:
17875342
8.

Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.

Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS, Sauerwein RW, Matile H, Zurbriggen R, Mazier D, Robinson JA, Pluschke G.

Chem Biol. 2007 May;14(5):577-87.

9.

Matrix metalloproteinase-19 expression in keratinocytes is repressed by transcription factors Tst-1 and Skn-1a: implications for keratinocyte differentiation.

Beck IM, Müller M, Mentlein R, Sadowski T, Mueller MS, Paus R, Sedlacek R.

J Invest Dermatol. 2007 May;127(5):1107-14. Epub 2006 Dec 28.

10.

Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1.

James S, Moehle K, Renard A, Mueller MS, Vogel D, Zurbriggen R, Pluschke G, Robinson JA.

Chembiochem. 2006 Dec;7(12):1943-50.

PMID:
17068840
11.

Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria.

Mueller MS, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L.

Trans R Soc Trop Med Hyg. 2004 May;98(5):318-21.

PMID:
15109558
12.

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites.

Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW, Van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D.

J Biol Chem. 2004 Mar 5;279(10):9490-6. Epub 2003 Dec 15.

13.

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.

Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, Robinson JA, Pluschke G.

Infect Immun. 2003 Aug;71(8):4749-58.

14.

Identification and characterization of a conserved, stage-specific gene product of Plasmodium falciparum recognized by parasite growth inhibitory antibodies.

Daubenberger CA, Diaz D, Curcic M, Mueller MS, Spielmann T, Certa U, Lipp J, Pluschke G.

Infect Immun. 2003 Apr;71(4):2173-81.

Supplemental Content

Loading ...
Support Center